Tag Archive | "epidermal growth factor receptor"
New DNA therapy for advanced mouth cancer
Source: www.dentistry.co.uk Author: staff A research team has been awarded a patent after developing a new DNA therapy for head and neck cancer sufferers. Researchers from the University of Pittsburgh School of Medicine in the US, aims to develop a safe and effective alternative to standard chemotherapy treatments which cause debilitating side-effects. Based on a form of [...]
Continue reading...Pitt researchers receive patent for new head and neck cancer treatment
Sunday, January 31, 2010
Source: www.healthcanal.com Author: staff Researchers from the University of Pittsburgh School of Medicine have been awarded a patent from the U.S. Patent and Trademark Office for the development of a new DNA therapy for head and neck cancers. The therapy targets the epidermal growth factor receptor (EGFR), a protein found on the surface of many types of [...]
Continue reading...Gefitinib shows promise as treatment for advanced head and neck cutaneous squamous cell carcinoma
Wednesday, July 15, 2009
Source: www.docguide.com Author: Louise Gagnon Gefitinib produces a significant response in patients with advanced head and neck cutaneous squamous cell carcinoma (cSCC) prior to standard treatment, according to a phase 2 study presented here at the 2nd World Congress of the International Academy of Oral Oncology (IAOO). “We want to shrink the tumour as much as we can [...]
Continue reading...Vanderbilt-Ingram Cancer Center’s research efforts highlighted at annual cancer conference
Saturday, June 27, 2009
Source: www.mc.vanderbilt.edu Author: Dagny Stuart A new drug which targets a genetic mutation found in more than 50 percent of melanoma cases, 10 percent to 15 percent of colorectal tumors and 8 percent of other solid tumors, caused tumor shrinkage and extended progression-free survival among patients during a recent Phase 1 clinical trial. Igor Puzanov, M.D., assistant [...]
Continue reading...Monoclonal Antibody Drugs for Cancer Treatment
Sunday, April 5, 2009
Source: www.newswise.com Author: staff The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects. For several types of cancer, monoclonal antibodies have already offered this advantage [...]
Continue reading...Tarceva® and Avastin® safe and effective for patients with squamous-cell head and neck carcinoma
Friday, March 6, 2009
Source: professional.cancerconsultants.com Author: staff Researchers from the National Cancer Institute and the University of Chicago have reported that the combination of Tarceva® (erlotinib) and Avastin® (bevacizumab) is well tolerated and produces sustained responses in some patients with recurrent or metastatic squamous-cell head and neck carcinoma. The details of this study appeared in the March 2009 issue of [...]
Continue reading...YM Biosciences’s drug selected for Phase III head and neck cancer study
Wednesday, January 7, 2009
Source: www.pharmaceutical-business-review.com Author: staff YM BioSciences, an oncology company, has announced that the National Cancer Centre of Singapore has selected nimotuzumab, the company’s EGFR-targeting drug, for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck. The National Cancer Centre of Singapore (NCCS) said that it selected nimotuzumab [...]
Continue reading...Merck Serono’s Erbitux nominated for International Prix Galien Award – transforming head and neck cancer treatment
Wednesday, October 15, 2008
Source: www.medicalnewstoday.com Author: staff Merck Serono’s Erbitux® is one of the finalists for the prestigious International Prix Galien Award for excellence in pharmaceutical development and innovation due to its role in transforming the treatment of head and neck cancer. Erbitux is the first and only targeted therapy approved for the treatment of squamous cell carcinoma of the head [...]
Continue reading...Erbitux – first treatment in 30 years to prolong survival in 1st-line recurrent and/or metastatic head and neck cancer
Monday, September 15, 2008
Source: www.medicalnewstoday.com Author: staff Data presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm demonstrate that the addition of Erbitux® (cetuximab) to platinum-based chemotherapy increases overall survival (OS) compared to chemotherapy alone in the 1st-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).1 Furthermore the [...]
Continue reading...- Samuel Broder: Why Isn't There a Gardasil for Men?
- Snus news & other tobacco products
- High dosage brachytherapy obtains excellent results in head and neck tumors
- A vaccine debate once focused on sex shifts as boys join the target market
- Consistent evidence to support the use of xylitol- and sorbitol-containing chewing gum to prevent dental caries
- Bill would bar sales of dissolvable tobacco
- R. J. Reynolds introducing 'dissolvable' tobacco
- Smoking debate has become nicotine-delivery debate
- Israeli study sees link between oral cancer, cell phones
- Periodontitis associated with fourfold increased risk for squamous cell carcinoma of the head and neck
- hilllaguna: Negating that nicotine replacement therapies are p...
- OC Advocate: It comes a little surprise that this "test" which ...
- hilllaguna: By world medical treatment standards a diagnosis t...
- Oral Cancer Foundation News Team: After sending this retrospective look to major can...
- hilllaguna: The mathematical probably that you have been expos...
- Office-Based Ultrasound-Guided FNA Found To Be Superior In Diagnosing Head And Neck Lesions
- Why men’s health is a feminist issue
- BT Pharma secures EUR 13.1million (USD 17.7 million) in capital funding and changes its name to Genticel
- Cancer survivor tells his experience with smokeless tobacco
- Mayo oral cancer study shows full tumor genome
- Viagra, Cialis do more than arouse
- Avoid incense
- Transoral robotic surgery showed good oncologic, functional outcomes
- Prolonged treatment delay did not affect outcomes in SCCHN
- Instant screening device is the best defense for detecting deadly oral cancer
Follow OCF on these social networking sites connect to us, get involved, spread the knowledge, help the cause, change the world.
Sunday, February 7, 2010
0 Comments